3054 Stock Overview
Operates in the biomedical science industry. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LIWANLI Innovation Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$22.25 |
| 52 Week High | NT$24.60 |
| 52 Week Low | NT$19.10 |
| Beta | 0.094 |
| 11 Month Change | -0.22% |
| 3 Month Change | 7.49% |
| 1 Year Change | 8.54% |
| 33 Year Change | -11.35% |
| 5 Year Change | -4.09% |
| Change since IPO | -89.40% |
Recent News & Updates
Shareholder Returns
| 3054 | TW Tech | TW Market | |
|---|---|---|---|
| 7D | 0.5% | 1.5% | 0.8% |
| 1Y | 8.5% | 26.3% | 30.3% |
Return vs Industry: 3054 underperformed the TW Tech industry which returned 26.3% over the past year.
Return vs Market: 3054 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 3054 volatility | |
|---|---|
| 3054 Average Weekly Movement | 4.7% |
| Tech Industry Average Movement | 5.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 3054 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 3054's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | n/a | n/a | www.liwanli.com.tw |
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry. It provides products in the areas of nutrition and healthcare. The company offers Vigoway and powder collection products for male, female, elderly, and children audience.
LIWANLI Innovation Co., Ltd. Fundamentals Summary
| 3054 fundamental statistics | |
|---|---|
| Market cap | NT$1.81b |
| Earnings (TTM) | -NT$16.07m |
| Revenue (TTM) | NT$95.94m |
18.7x
P/S Ratio-111.6x
P/E RatioIs 3054 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3054 income statement (TTM) | |
|---|---|
| Revenue | NT$95.94m |
| Cost of Revenue | NT$76.75m |
| Gross Profit | NT$19.20m |
| Other Expenses | NT$35.27m |
| Earnings | -NT$16.07m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 20.01% |
| Net Profit Margin | -16.75% |
| Debt/Equity Ratio | 0% |
How did 3054 perform over the long term?
See historical performance and comparison